MNKPF News and Press, Mallinckrodt

Mallinckrodt plc Reports Fourth Quarter and Fiscal 2022 Financial Results and Provides 2023 Guidance PR Newswire Made Solid Progress on Launch of Terlivaz® with Significant Medical Community Interest Appointed Chief Scientific Officer with Proven Record of Executi...

Mallinckrodt to Present at Cowen's 43rd Annual Health Care Conference PR Newswire DUBLIN , Feb. 16, 2023 /PRNewswire/ -- Mallinckrodt plc (NYSE American: MNK), a global specialty pharmaceutical company, today announced that Siggi Olafsson , President ...

Mallinckrodt plc Reports Third Quarter 2022 Financial Results and Reaffirms Guidance PR Newswire Launched Terlivaz ® Following U.S. Food and Drug Administration (FDA) Approval in September; Submitted U.S. FDA Premarket Notification Application for Next-Generat...

Mallinckrodt to Present Data on TERLIVAZ® (terlipressin) for Injection in Adult Patients with Hepatorenal Syndrome (HRS) at the American Association for the Study of Liver Diseases (AASLD) 2022 Liver Meeting PR Newswire – Seven scientific abstracts spanning c...

Mallinckrodt to Present Data on TERLIVAZ® (terlipressin) for Injection in Adult Patients with Hepatorenal Syndrome (HRS) at the American College of Gastroenterology (ACG) Annual Scientific Meeting PR Newswire – Five scientific abstracts spanning clinical...

Mallinckrodt Receives Approval to List on NYSE American PR Newswire Trading on NYSE American Expected to Commence Under Ticker Symbol "MNK" on October 27, 2022 DUBLIN , Oct. 24, 2022 /PRNewswire/ -- Mallinckrodt plc (OTCMKTS: MNKPF) (" M...

Mallinckrodt to Report Earnings Results for Third Quarter 2022 PR Newswire DUBLIN , Oct. 18, 2022 /PRNewswire/ -- Mallinckrodt plc (OTCMKTS: MNKPF ), a global specialty pharmaceutical company, today announced that it will report third quarter 20...

Mallinckrodt Announces Appointment of Susan Silbermann to its Board of Directors PR Newswire DUBLIN , Oct. 6, 2022 /PRNewswire/ -- Mallinckrodt plc (OTCMKTS: MNKPF) (" Mallinckrodt " or the "Company"), a global specialty pharmaceutical company, to...

Mallinckrodt ( NYSE: MNK ) ( OTCPK:MNKPF ) said it filed a 510(k) premarket notification application to the U.S. Food and Drug Administration (FDA) seeking clearance for an inhaled nitric oxide delivery system for INOmax (nitric oxide) gas for inhalation. ...

Mallinckrodt Announces Submission of 510(k) to the U.S. FDA for Inhaled Nitric Oxide Delivery System PR Newswire — If 510(k) cleared, this next-generation investigational inhaled nitric oxide delivery system would be the latest in a long line of dual channel del...